853029-57-9

• 常用中文名：利拉利汀母核
• 常用英文名：8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
• CAS号：853029-57-9
• 分子式：C₂₀H₁₇BrN₆O₂
• 分子量：453.292
• 相关类别： 医药中间体 原料药中间体
• 发布时间：2018-04-11 08:00:00
• 更新时间：2026-07-12 09:13:55

名称

• 中文名: 8-溴-7-(2-丁炔-1-基)-3,7-二氢-3-甲基-1-[(4-甲基-2-喹唑啉基)甲基]-1H-嘌呤-2,6-二酮
• 英文名: 8-bromo-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
• 中文别名: 利拉利汀中间体F; 8-溴-7-(2-丁炔-1-基)-3,7-二氢-3-甲基-1-((4-甲; 利拉利汀中间体,8-溴-7-(2-丁炔-1-基)- 3,7-二氢-3-甲基-1-[(4-甲 基-2-喹唑啉基)甲基]-1H- 嘌呤-2,6-二酮; 8-溴-7-(2-丁炔-1-基)-3,7-二氢-3-甲基-1-[(4-甲基-2-喹唑啉基)甲基]-1H-嘌呤-2,6-二酮 利拉利汀母核; 利拉利汀母; 8-溴-7-(2-丁炔-1-基)-3,7-二氢-3-甲基-1-[(4-甲基-2-喹唑基)甲基]-1H-嘌呤-2,6-二酮9; 8-溴-7-(2-丁炔基)-3-甲基-1-((4-甲基喹唑啉-2-基)甲基)-黄嘌呤; 利拉利汀母核 853-9; 利拉列汀母核; 8-溴-7-(2-丁炔-1-基)-3,7-二氢-3-甲基-1-[(4-甲基-2-喹唑啉基)甲; 利格列汀杂质32; 8-溴-7-(2-丁炔-1-基)-1-[(4-甲基-2-喹唑啉基)甲基]-3-甲基黄嘌呤; 利拉利汀杂质48; 8-溴-7-(丁-2-炔-1-基)-3-甲基-1-[(4-甲基喹唑啉-2-基)甲基]-3,7-二氢-1H-嘌呤-2,6-二酮; 利拉利汀杂质32; 8-溴-7-丁炔-3-甲基-1-(4-甲基-喹唑啉-2-甲基)-3,7-二氢-嘌呤-2,6-二酮; 8-溴-7-(2-丁炔-1-基)-3,7-二氢-3-甲基-1-[(4-甲基-2-喹唑啉基)甲基]-1H-嘌呤-2,6; 8-溴-7-(2-丁炔-1-基)-3,7-二氢-3-甲基-1-[(4-甲基-2-喹唑啉基)甲基H-嘌呤-2,6-二酮; 8-溴-7-(2-丁炔基)-3-甲基-1-((4-甲基喹唑啉-2-基)甲基)-1H-嘌呤-2,6(3H,7H)-二酮; 利拉利汀目核; 8-溴-7-(2-丁炔)-3-甲基-1-((4-甲基喹唑啉-2-基)甲基)-黄嘌呤; 8-溴-7-(2-丁炔)-3-甲基-1-((4-甲基喹唑啉-2-基)甲基)-黄瞟呤; 利拉列汀母核(利拉列汀中间体); 利格列汀杂质LINA05; 利拉利汀中间体1; 利格列汀杂质94; 利格列汀溴代物; 8-溴-7-(2-丁炔-1-基)-3,7-二氢-3-甲基-1-[(4-甲基-2-喹唑基)甲基]-1H-嘌呤-2,6-二酮; 1-[(4-甲基-2-喹唑啉基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-溴-3,7-二氢-1H-嘌呤-2,6-二酮
• 英文别名: 8-BroMo-7-(2-butyn-a-yl)-3,7-dihydro-3-Methyl-1-[(4-Methyl-2-quinazolinyl)Methyl]-1H-purine-2,6-dione; Linaint-H; 8-Bromo-7-(2-Butyn-1-Yl)-3,7-Dihydro-3-Methyl-1-[(4-Methyl-2-Quinazolinyl)Methyl]-1H-Purine-2,6-Dione / Linagliptin Intermediate; 1-[(4-Methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl) 8-bromoyanthine; 1-[(4-METHYLQUINAZOLIN-2-YL)METHYL]-3-METHYL-7-(2; 1H-Purine-2,6-dione,8-broMo-7-(2-butynyl)-3,7-dihydro-3-Methyl-1-[(4-Methyl-2-quinazolinyl)Methyl]; 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione ISO 9001：2015 REACH; 8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquin-azolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-d; Linagliptin Impurity 32; 8-bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione; 1H-Imidazole-4-cboxaldehyde,8-methyl; Linagliptin Impurity 94; 8-Bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dion; 1-[(4-Methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromoxanthine; 8-BroMo-7-but-2-ynyl-3-Methyl-1-(4-Methyquinazolin-2-ylMethyl)-3,7-dihydro-purine-2,6-dione; Linagliptin intermediate 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromoxanthine; 8-BROMO-7-BUT-2-YNYL-3-METHYL-1-(4-METHYL-QUINAZOLIN-2-YLMETHYL)-3,7-DIHYDRO-PURINE-2,6-DIONE 853-9; 1H-Purine-2,6-dione,8-bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]; 8-bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl); 8-Broma-7 -( but-2-yn-1-yl)-3-methyl-1-[[4-methylquinazalin-2-ylimethiyl]-3,7-dihydra-1H-purine-2,6-dione; 2-bromo-1-(but-2-ynyl)-4-methyl-6-((4-methylquinazolin-2-yl)methyl)-1H-imidazo[4,5-b]pyridine-5,7-(4H,6H)-dione; Iinagliptin Intermediate3; Linagliptinmothernucleus; Linagliptin-1; 8-Bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione; 8-BroMo-7-(but-2-yn-1-yl)-3-Methyl-1-((4-Methylquinazolin-2-yl)Methyl)-1H-purine-2,6(3H,7H)-dione; X4789; 8-brom-7- (2-butynyl-1-yl) -3,7-dihydro-3-methyl-1- [(4-methyl-2-quinazolino) methyl] -1H-purine-2,6-dione; LIP-1A IMPURITY; 8-bromo-7-(but-2-ynyl)-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione; Linagliptin Related Compound-11 (Bromo compound); (2-(chloromethyl)-4-methylquinazoline)，8-Bromo-7-but-2-ynyl-3-methyl-1-(4- methyl-quinazolin-2-ylmethyl)-3,7- dihydro-purine-2,6-dione; 8-bromo-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione; 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-xanthine; 8-broMo-7-(but-2-ynyl)-3-Methyl-1-((4-Methylquinazolin-2-yl)Methyl)-1H-purine-2,6(3H,7H)-dione; 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromoxanthine; 1H-Purine-2,6-dione, 8-bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]; Linagliptin interMediate F; Linagliptin IntermediateLinagliptin Intermediate; 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl; 8-bromo-7-(2-butyne)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-xanthine; 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(but-2-ynyl)-8-bromo-xanthine; 8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquin-azolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dion; 1-[(4-Methylquinazolin-2-yl)Methyl]-3-Methyl-7-(2-butin-1-yl)-8-broMoxanthine; 8- bromo -7-(2- butyn -1- yl) -3,7- dihydro -3- methyl -1-[(4- methyl -2- quinazolinyl) methyl ]-1H- purin -2,6- dione; 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromoxanthine; 8-Bromo-7-but

物化性质

• 密度: 1.6±0.1 g/cm3
• 沸点: 602.9±65.0 °C at 760 mmHg
• 分子式: C₂₀H₁₇BrN₆O₂
• 分子量: 453.292
• 闪点: 318.4±34.3 °C
• 精确质量: 452.059631
• PSA: 87.60000
• LogP: 3.96
• 蒸汽压: 0.0±1.7 mmHg at 25°C
• 折射率: 1.713
• 储存条件: 2-8°C

安全

• 海关编码: 2933990090

合成路线

666816-98-4 109113-72-6 ~95% 853029-57-9

文献：WO2005/51950 A1, ; Page/Page column 18 ;

666816-98-4 ~% 853029-57-9

文献：Journal of Medicinal Chemistry, , vol. 50, # 26 p. 6450 - 6453

上下游产品

上游产品  2
666816-98-4 109113-72-6
下游产品  0

海关

海关编码	2933990090
中文概述	2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%